The Progenics Pharmaceuticals’ (PGNX) Buy Rating Reaffirmed at Needham & Company LLC

The Progenics Pharmaceuticals’ (PGNX) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) in a research note released on Tuesday.

A number of other research analysts have also recently commented on the company. Brean Capital initiated coverage on Progenics Pharmaceuticals in a research note on Tuesday. They set a buy rating and a $11.00 price target on the stock. Zacks Investment Research upgraded Progenics Pharmaceuticals from a hold rating to a buy rating and set a $6.75 price objective on the stock in a research note on Tuesday, July 26th. BTIG Research reiterated a buy rating and issued a $9.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. Finally, Jefferies Group reiterated a buy rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $9.35.

Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) traded down 0.780% during mid-day trading on Tuesday, reaching $6.995. The company’s stock had a trading volume of 201,616 shares. Progenics Pharmaceuticals has a 52 week low of $3.61 and a 52 week high of $8.37. The company’s 50-day moving average is $6.35 and its 200-day moving average is $5.39. The stock’s market capitalization is $489.55 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. Progenics Pharmaceuticals had a negative return on equity of 41.76% and a negative net margin of 203.56%. The company had revenue of $8.50 million for the quarter, compared to analysts’ expectations of $6.33 million. During the same period in the prior year, the firm earned ($0.17) earnings per share. The firm’s revenue was up 337.6% compared to the same quarter last year. Equities analysts predict that Progenics Pharmaceuticals will post $0.13 EPS for the current year.

A number of institutional investors have recently bought and sold shares of PGNX. Integre Asset Management LLC raised its position in Progenics Pharmaceuticals by 118.1% in the first quarter. Integre Asset Management LLC now owns 59,648 shares of the company’s stock valued at $260,000 after buying an additional 32,293 shares during the period. Cadence Capital Management LLC raised its position in Progenics Pharmaceuticals by 23.8% in the second quarter. Cadence Capital Management LLC now owns 192,675 shares of the company’s stock valued at $813,000 after buying an additional 37,048 shares during the period. Princeton Alpha Management LP acquired a new position in Progenics Pharmaceuticals during the second quarter valued at approximately $100,000. A.R.T. Advisors LLC raised its position in Progenics Pharmaceuticals by 241.6% in the first quarter. A.R.T. Advisors LLC now owns 307,523 shares of the company’s stock valued at $1,340,000 after buying an additional 217,500 shares during the period. Finally, Gamco Investors INC. ET AL acquired a new position in Progenics Pharmaceuticals during the second quarter valued at approximately $106,000. 84.22% of the stock is currently owned by hedge funds and other institutional investors.

About Progenics Pharmaceuticals

Related posts

Leave a Comment